儿童间质性肺疾病国际管理平台(chILD-EU)
chILD-EU 建立了基于网络的儿童间质性肺疾病管理平台,含注册登记与生物样本库。3 年内纳入 575 例患者,346 例完成五家国际中心的多学科复核,其中 13% 的转诊诊断未被同行复核确认。25 例复杂病例的亚分类评估显示,首次评估的精确一致率为 59%,培训后为 64%。
要点
- chILD-EU 平台可对儿童间质性肺疾病进行国际多学科复核与长期随访。
- 同行复核使 13% 的转诊诊断被修正,其中 27% 为错误诊断。
- 亚分类系统首次评估一致率 59%,培训后 64%,仅 10% 的错误答案落入错误类别。
核心结论
- chILD-EU 已建立平台以辅助儿童间质性肺疾病的临床评估。
- 亚分类系统可用于诊断分类,但需培训以达到最佳实施效果。
研究设计与样本
- 设计并实施基于网络的 chILD 管理平台,包含注册登记与生物样本库。
- 3 年内纳入 575 例患者进行观察,覆盖广泛的 chILD 谱系。
- 346 例患者由五家国际中心(慕尼黑 51%、伦敦 12%、汉诺威 31%、安卡拉 1%、巴黎 5%)完成多学科复核。
- 使用 25 例复杂 chILD 病例评估诊断亚分类系统的质量与可重复性。
主要发现
- 在 13% 的病例中,转诊团队诊断未被同行复核确认。
- 未被确认的诊断中,27% 为初始诊断错误,50% 为不精确,23% 为补充了重要信息。
- 九位专家临床医生将最终诊断归入 chILD-EU 注册分类的总体精确一致率首次评估为 59%,培训后为 64%。
- 仅 10% 的「错误」答案导致分配到错误类别。
关键数值与推荐
- 多学科复核由五家国际中心完成,各中心复核占比:慕尼黑 51%、伦敦 12%、汉诺威 31%、安卡拉 1%、巴黎 5%。
- 亚分类精确一致率首次评估 59%,培训后 64%。
- 「错误」答案中仅 10% 落入错误类别。
临床怎么用
- 可将 chILD 病例提交国际管理平台进行独立多学科复核,以提高诊断准确性。
- 采用 chILD-EU 注册分类进行亚分类时,需对临床医生进行培训以优化实施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Children's interstitial lung diseases (chILD) cover many rare entities, frequently not diagnosed or studied in detail. There is a great need for specialised advice and for internationally agreed subclassification of entities collected in a register.Our objective was to implement an international management platform with independent multidisciplinary review of cases at presentation for long-term follow-up and to test if this would allow for more accurate diagnosis. Also, quality and reproducibility of a diagnostic subclassification system were assessed using a collection of 25 complex chILD cases. METHODS: A web-based chILD management platform with a registry and biobank was successfully designed and implemented. RESULTS: Over a 3-year period, 575 patients were included for observation spanning a wide spectrum of chILD. In 346 patients, multidisciplinary reviews were completed by teams at five international sites (Munich 51%, London 12%, Hannover 31%, Ankara 1% and Paris 5%). In 13%, the diagnosis reached by the referring team was not confirmed by peer review. Among these, the diagnosis initially given was wrong (27%), imprecise (50%) or significant information was added (23%).The ability of nine expert clinicians to subcategorise the final diagnosis into the chILD-EU register classification had an overall exact inter-rater agreement of 59% on first assessment and after training, 64%. Only 10% of the 'wrong' answers resulted in allocation to an incorrect category. Subcategorisation proved useful but training is needed for optimal implementation. CONCLUSIONS: We have shown that chILD-EU has generated a platform to help the clinical assessment of chILD. TRIAL REGISTRATION NUMBER: Results, NCT02852928.
引用
- Griese M, Seidl E, Hengst M, et al. International management platform for children's interstitial lung disease (chILD-EU). Thorax. 2017. PMID: 29056600. doi:10.1136/thoraxjnl-2017-210519
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。